Understanding a Key Energy Regulator for Health Conditions
PGC1alpha Pathway: Novel Intracellular and Extracellular Mediators
This research explores how a vital energy regulator in our bodies, called PGC1alpha, works to help us understand and develop new treatments for conditions like obesity, diabetes, and certain brain and muscle disorders.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11120959 on NIH RePORTER |
What this research studies
Our bodies rely on a process called PGC1alpha to manage energy and metabolism in many tissues. When this process doesn't work correctly, it can contribute to serious health issues such as obesity, diabetes, and various neurological and muscle diseases. This project aims to uncover the detailed ways PGC1alpha is controlled within our cells. We are particularly interested in a newly identified factor, RBM43, which appears to influence PGC1alpha levels and activity. By understanding how RBM43 affects PGC1alpha, we hope to find new ways to restore healthy energy balance and develop effective treatments.
Who could benefit from this research
Good fit: This foundational research is not directly recruiting patients but aims to benefit future patients with conditions related to energy metabolism, obesity, diabetes, and neurological or neuromuscular disorders.
Not a fit: Patients without conditions related to energy metabolism or the specific diseases mentioned are unlikely to directly benefit from this particular research.
Why it matters
Potential benefit: If successful, this work could lead to the development of new medications or therapies for patients suffering from obesity, diabetes, and various neurological and neuromuscular disorders.
How similar studies have performed: Previous work by this research group has already shown that PGC1alpha is controlled in important ways, and this project builds on those findings by exploring novel regulatory factors.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Spiegelman, Bruce M. — Dana-Farber Cancer Inst
- Study coordinator: Spiegelman, Bruce M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.